These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 16468238

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF.
    Cancer; 2005 May 01; 103(9):1850-5. PubMed ID: 15786422
    [Abstract] [Full Text] [Related]

  • 23. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
    Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Saulnier PJ, Roy L, Guilhot F, Turhan AG.
    Leuk Res; 2009 Apr 01; 33(4):551-5. PubMed ID: 18829107
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
    Kreuzer KA, Le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K, Hochhaus A, Dörken B.
    Ann Hematol; 2003 May 01; 82(5):284-9. PubMed ID: 12692682
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA, Pan Q, Ladanyi M, Steinherz PG.
    Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284
    [Abstract] [Full Text] [Related]

  • 28. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F.
    Leuk Res; 2008 Feb 15; 32(2):255-61. PubMed ID: 17692911
    [Abstract] [Full Text] [Related]

  • 29. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, Sasaki H, Kyo T, Jinnai I, Bessyo M, Miyamura K.
    Rinsho Ketsueki; 2009 Jun 15; 50(6):481-7. PubMed ID: 19571508
    [Abstract] [Full Text] [Related]

  • 30. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
    Hughes T, Branford S.
    Blood Rev; 2006 Jan 15; 20(1):29-41. PubMed ID: 16426942
    [Abstract] [Full Text] [Related]

  • 31. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
    Moravcová J, Brdicka R.
    Cas Lek Cesk; 2005 Jan 15; 144(1):32-7. PubMed ID: 15789779
    [Abstract] [Full Text] [Related]

  • 32. [Prognostic efficacy for measurement of real-time quantitative PCR-based major bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
    Takahata M, Hashino S, Fujisawa F, Kondo T, Ota S, Kobayashi S, Tanaka J, Imamura M, Asaka M.
    Rinsho Ketsueki; 2004 Dec 15; 45(12):1241-6. PubMed ID: 15678915
    [Abstract] [Full Text] [Related]

  • 33. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B.
    Cancer Genet Cytogenet; 2005 Jun 15; 159(2):164-7. PubMed ID: 15899391
    [Abstract] [Full Text] [Related]

  • 34. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y, Jiang Q, Jiang H, Li LD, Chang Y, Huang XJ, Chen SS.
    Int J Lab Hematol; 2008 Aug 15; 30(4):317-23. PubMed ID: 18665830
    [Abstract] [Full Text] [Related]

  • 35. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 36. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.
    J Clin Oncol; 2005 Oct 20; 23(30):7583-93. PubMed ID: 16234522
    [Abstract] [Full Text] [Related]

  • 37. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.
    Haematologica; 2004 Jan 20; 89(1):49-57. PubMed ID: 14754606
    [Abstract] [Full Text] [Related]

  • 38. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.
    Haematologica; 2008 Feb 20; 93(2):186-92. PubMed ID: 18223278
    [Abstract] [Full Text] [Related]

  • 39. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
    Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M.
    Cancer Genet Cytogenet; 2005 Oct 01; 162(1):57-62. PubMed ID: 16157201
    [Abstract] [Full Text] [Related]

  • 40. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH, Tang JL, Chen RL, Li CC, Lee CP.
    Leuk Res; 2008 Nov 01; 32(11):1724-34. PubMed ID: 18603297
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.